These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 34624138

  • 1. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
    Kachhawa G, Senthil Kumar KV, Kulshrestha V, Khadgawat R, Mahey R, Bhatla N.
    Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
    [Abstract] [Full Text] [Related]

  • 2. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
    Pustotina O, Myers SH, Unfer V, Rasulova I.
    Gynecol Obstet Invest; 2024 Aug; 89(2):131-139. PubMed ID: 38295772
    [Abstract] [Full Text] [Related]

  • 3. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study.
    La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A.
    Gynecol Endocrinol; 2015 Jan; 31(1):52-6. PubMed ID: 25268566
    [Abstract] [Full Text] [Related]

  • 4. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
    Fruzzetti F, Capozzi A, Canu A, Lello S.
    Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 6. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
    Januszewski M, Issat T, Jakimiuk AA, Santor-Zaczynska M, Jakimiuk AJ.
    Ginekol Pol; 2019 Aug 18; 90(1):7-10. PubMed ID: 30756365
    [Abstract] [Full Text] [Related]

  • 7. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
    Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F.
    Trends Endocrinol Metab; 2018 Nov 18; 29(11):768-780. PubMed ID: 30270194
    [Abstract] [Full Text] [Related]

  • 8. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M, Basciani S, Camajani E.
    Eur Rev Med Pharmacol Sci; 2019 Jun 18; 23(12):5512-5521. PubMed ID: 31298405
    [Abstract] [Full Text] [Related]

  • 9. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May 18; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 10. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE, Unfer V.
    Gynecol Endocrinol; 2015 Jul 18; 31(7):501-5. PubMed ID: 26177098
    [Abstract] [Full Text] [Related]

  • 11. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
    Facchinetti F, Unfer V, Dewailly D, Kamenov ZA, Diamanti-Kandarakis E, Laganà AS, Nestler JE, Soulage CO, Group of 'Inositol in PCOS and Reproduction'.
    Trends Endocrinol Metab; 2020 Jun 18; 31(6):435-447. PubMed ID: 32396844
    [Abstract] [Full Text] [Related]

  • 12. Myo-inositol vs. D-chiro inositol in PCOS treatment.
    Formuso C, Stracquadanio M, Ciotta L.
    Minerva Ginecol; 2015 Aug 18; 67(4):321-5. PubMed ID: 25670222
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G, Unfer V, Harrath AH, Bizzarri M.
    Gynecol Endocrinol; 2017 Jan 18; 33(1):1-9. PubMed ID: 27898267
    [Abstract] [Full Text] [Related]

  • 16. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
    J Clin Pharmacol; 2014 Oct 18; 54(10):1079-92. PubMed ID: 25042908
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial.
    Bahadur A, Arora H, Ravi AK, Naithani M, Bahurupi Y, Chaturvedi J, Ajmani M, Mundhra R.
    Cureus; 2021 Jun 18; 13(6):e15510. PubMed ID: 34268040
    [Abstract] [Full Text] [Related]

  • 18. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V, Porcaro G.
    Expert Rev Clin Pharmacol; 2014 Sep 18; 7(5):623-31. PubMed ID: 24898153
    [Abstract] [Full Text] [Related]

  • 19. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome.
    Lete I, Martínez A, Lasaga I, Centurión E, Vesga A.
    Gynecol Endocrinol; 2024 Dec 18; 40(1):2301554. PubMed ID: 38239032
    [Abstract] [Full Text] [Related]

  • 20. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
    Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, Kamenov ZA, Bevilacqua A, Carlomagno G, Gerli S, Oliva MM, Devroey P.
    Eur J Obstet Gynecol Reprod Biol; 2015 Dec 18; 195():72-76. PubMed ID: 26479434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.